MetaVia Inc. Share Price
MTVAMetaVia Inc. Stock Performance
Open $1.85 | Prev. Close $1.73 | Circuit Range N/A |
Day Range $1.78 - $1.90 | Year Range $0.56 - $12.68 | Volume 6,371 |
Average Traded $1.84 |
MetaVia Inc. Share Price Chart
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MetaVia Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
04-Feb-26 | $1.99 | $1.90 | +0.80% |
03-Feb-26 | $2.37 | $1.89 | -18.04% |
02-Feb-26 | $2.53 | $2.30 | -5.35% |
30-Jan-26 | $2.38 | $2.43 | +2.53% |
29-Jan-26 | $2.37 | $2.37 | +1.28% |
28-Jan-26 | $2.45 | $2.34 | -10.34% |
27-Jan-26 | $2.78 | $2.61 | -5.78% |